2017 Blue Ribbon Highlights

Blue Ribbon Highlights Session Recognizes Best Posters from 21st International Congress of Parkinson’s Disease and Movement Disorders


VANCOUVER – The annual Blue Ribbon Highlights Session took place on Thursday, June 8, during the 21st International Congress of Parkinson’s Disease and Movement Disorders. This special session provides a critical review of the best poster presentations by a panel of experts, highlighting the relevance, nov­elty, and quality of both clinical and basic research presented by delegates.

Of the more than 1,500 abstracts accepted for presentation at this year’s International Congress, only 24 were given this special recognition. The Blue Ribbon Highlights Session was chaired by Claudia Trenkwalder, Germany, Paolo Calabresi, Italy, and Oksana Suchowersky, Canada. 

The poster numbers chosen for the 2017 Blue Ribbon Highlights include:

  • 557: Parkinson’s Disease-Like Pathology in the Rat Brain and Colon Following Methamphetamine Self-Administration
  • LBA 13: Lack of Rhes protein increases dopamine neurons degeneration and neuroinflammation in a gender dependent manner
  • 531: Neuroinflammation in the substantia nigra is triggered by synucleinopathy and precedes nigral degeneration
  • 507: Skin nerve phosphorylated α-synuclein deposits in idiopathic REM sleep behavior disorder.
  • 840: Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
  • 120: Efficacy of Tozadenant in Animal Models of Non-Motor Symptoms of Parkinson’s Disease
  • LBA 21: Tissue Engineered Nigrostriatal Pathway for Treatment of Parkinson’s Disease
  • 1451: Interactions between amyloid-β and microglial activation in Parkinson’s disease
  • 536: New device HANABI (HANdai Amyloid Burst Inducer) is a rapid and sensitive detecting system of α synuclein fibril in CSF from Parkinson’s disease patients
  • 1474: Metabolic changes following transcranial magnetic resonance-guided focused ultrasound subthalamotomy
  • 1039: Progression to Parkinson’s disease in carriers of LRRK2 G2019S mutation: a 4-year prospective study with serial dopamine transporter imaging
  • 66: Parkinson Disease-Associated Polyneuropathy: A Biomarker of Disease Severity?
  • 1074: Systematic Evaluation of Major and Minor Psychotic Symptoms in Parkinson’s Disease
  • 53: Real-world non-motor score changes in Parkinson’s disease patients with motor fluctuations: The J-FIRST study
  • 1557: Non-motor symptom burden is associated with thalamic atrophy in Parkinson’s disease
  • 1423: The effect of early STN-DBS in PD patients on axial symptoms: a 2-year randomized controlled trial (EARLYSTIM-Gait analysis)
  • 1558: Exercise alters response of reward anticipation in the ventral striatum of subjects with Parkinson’s disease
  • 1145: The Corticobasal Degeneration Functional Rating Scale (CBD-FS)
  • SG 09: Which clinical features predict progressive supranuclear palsy pathology? A clinicopathological study on 437 autopsy cases and a literature review
  • 178: Can the level of CSF Neurofilament Light Chain predict disease progression in Progressive Supranuclear Palsy?
  • 1185: A randomized, double-blind, placebo-controlled study of the D1 receptor antagonist ecopipam for children and adolescents with Tourette syndrome
  • 414: Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD): Efficacy, Safety, and Tolerability of Fixed-Dose Deutetrabenazine for the Treatment of Tardive Dyskinesia
  • 302: Physical but not mental aspects of health-related quality of life are improved in 10-year long-term follow-up of deep brain stimulation for segmental dystonia

For complete abstracts, Late Breaking Abstracts and author information, visit: www.mdscongress2017.org.
 

About the 21st International Congress of Parkinson's Disease and Movement Disorders: Meeting attendees gather to learn the latest research findings and state-of-the-art treatment options in Movement Disorders, including Parkinson's disease. Over 4,200 physicians and medical professionals from more than 90 countries were in attendance and could view over 1,500 scientific abstracts submitted by clinicians from around the world.

About the International Parkinson and Movement Disorder Society: The International Parkinson and Movement Disorder Society (MDS), an international society of over 5,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.

Top